Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 226

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

Open access
Campesato, Luís Felipe, Barroso-Sousa, Romualdo, Jimenez, Leandro, Correa, Bruna R., Sabbaga, Jorge, Hoff, Paulo M., Reis, Luiz F. L., Galante, Pedro Alexandre F., Camargo, Anamaria A. · 2015 · Oncotarget

Abstract

// Luís Felipe Campesato 1,2,3 , Romualdo Barroso-Sousa 2 , Leandro Jimenez 1,2 , Bruna R. Correa 2 , Jorge Sabbaga 2 , Paulo M. Hoff 2 , Luiz F. L. Reis 2 , Pedro Alexandre F. Galante 2 and Anamaria A. Camargo 1,2 1 Instituto Ludwig de Pesquisa sobre o Câncer, São Paulo, Brazil 2 Hospital Sírio-Libanês, São Paulo, Brazil 3 Departmento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil Correspondence to: Anamaria A. Camargo, email: // Keywords : cancer-gene panels, mutational load, PD-1 blockade, immunotherapy, response prediction Received : August 04, 2015 Accepted : September 04, 2015 Published : October 01, 2015 Abstract Cancer gene panels (CGPs) are already used in clinical practice to match tumor’s genetic profile with available targeted therapies. We aimed to determine if CGPs could also be applied to estimate tumor mutational load and predict clinical benefit to PD-1 and CTLA-4 checkpoint blockade therapy. Whole-exome sequencing (WES) mutation data obtained from melanoma and non-small cell lung cancer (NSCLC) patients published by Snyder et al. 2014 and Rizvi et al. 2015, respectively, were used to select nonsynonymous somatic mutations occurring in genes included in the Foundation Medicine Panel (FM-CGP) and in our own Institutional Panel (HSL-CGP). CGP-mutational load was calculated for each patient using both panels and was associated with clinical outcomes as defined and reported in the original articles. Higher CGP-mutational load was observed in NSCLC patients presenting durable clinical benefit (DCB) to PD-1 blockade (FM-CGP P =0.03, HSL-CGP P =0.01). We also observed that 69% of patients with high CGP-mutational load experienced DCB to PD-1 blockade, as compared to 20% of patients with low CGP-mutational load (FM-CGP and HSL-CGP P =0.01). Noteworthy, predictive accuracy of CGP-mutational load for DCB was not statistically different from that estimated by WES sequencing ( P =0.73). Moreover, a high CGP-mutational load was significantly associated with progression-free survival (PFS) in patients treated with PD-1 blockade (FM-CGP P =0.005, HR 0.27, 95% IC 0.105 to 0.669; HSL-CGP P =0.008, HR 0.29, 95% IC 0.116 to 0.719). Similar associations between CGP-mutational load and clinical benefit to CTLA-4 blockade were not observed. In summary, our data reveals that CGPs can be used to estimate mutational load and to predict clinical benefit to PD-1 blockade, with similar accuracy to that reported using WES.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5950

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 226

Metadata

Authors
Campesato, L. F., Barroso-Sousa, R., Jimenez, L., Correa, B. R., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A.
Venue
Oncotarget
Published
2015-10-01
Volume
6
Issue
33
Pages
34221-34227
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2175254188
Cited by
226
References
8
FWCI
9.36
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. https://app.cochat.ai/papers/10.18632/oncotarget.5950
The paper
Campesato, L. F., Barroso-Sousa, R., Jimenez, L., Correa, B. R., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015). Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget. https://doi.org/10.18632/oncotarget.5950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.